JP7580380B2 - 運動ニューロン疾患を処置するための方法及び組成物 - Google Patents

運動ニューロン疾患を処置するための方法及び組成物 Download PDF

Info

Publication number
JP7580380B2
JP7580380B2 JP2021545301A JP2021545301A JP7580380B2 JP 7580380 B2 JP7580380 B2 JP 7580380B2 JP 2021545301 A JP2021545301 A JP 2021545301A JP 2021545301 A JP2021545301 A JP 2021545301A JP 7580380 B2 JP7580380 B2 JP 7580380B2
Authority
JP
Japan
Prior art keywords
compound
pde
inhibitor
formula
ibudilast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524930A5 (enExample
JP2022524930A (ja
Inventor
アリグエル， ホセ マリア エストレラ
プラ， マリア エレナ オブラドール
ロサリオ サルヴァドール，
ライアン ダブリュー． デリンジャー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Valencia
Original Assignee
University of Valencia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Valencia filed Critical University of Valencia
Publication of JP2022524930A publication Critical patent/JP2022524930A/ja
Publication of JP2022524930A5 publication Critical patent/JP2022524930A5/ja
Application granted granted Critical
Publication of JP7580380B2 publication Critical patent/JP7580380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021545301A 2019-02-26 2020-02-25 運動ニューロン疾患を処置するための方法及び組成物 Active JP7580380B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810728P 2019-02-26 2019-02-26
US62/810,728 2019-02-26
US201962892754P 2019-08-28 2019-08-28
US62/892,754 2019-08-28
PCT/US2020/019600 WO2020176445A1 (en) 2019-02-26 2020-02-25 Methods and compositions for treating motor neuron diseases

Publications (3)

Publication Number Publication Date
JP2022524930A JP2022524930A (ja) 2022-05-11
JP2022524930A5 JP2022524930A5 (enExample) 2022-09-27
JP7580380B2 true JP7580380B2 (ja) 2024-11-11

Family

ID=72239986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545301A Active JP7580380B2 (ja) 2019-02-26 2020-02-25 運動ニューロン疾患を処置するための方法及び組成物

Country Status (5)

Country Link
US (1) US12350283B2 (enExample)
EP (1) EP3930728A1 (enExample)
JP (1) JP7580380B2 (enExample)
CN (1) CN113473993B (enExample)
WO (1) WO2020176445A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213420A1 (en) 2017-05-17 2018-11-22 Universitat De Valencia-Estudi General Treating and preventing motor neuron diseases using nicotinamide riboside

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219552A1 (en) * 2001-08-14 2004-11-04 Ali Ait Ikhlef Novel molecular target for neurotoxicity
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CN107849083A (zh) * 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
EP3429354A4 (en) * 2016-03-16 2020-03-25 Chromadex Inc. B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
US11286274B2 (en) * 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213420A1 (en) 2017-05-17 2018-11-22 Universitat De Valencia-Estudi General Treating and preventing motor neuron diseases using nicotinamide riboside

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2017年，Vol.8, Article 1005，p.1-12
Neuroreport，2000年，Vol.11, No.11，p.2491-2493

Also Published As

Publication number Publication date
CN113473993A (zh) 2021-10-01
WO2020176445A1 (en) 2020-09-03
EP3930728A1 (en) 2022-01-05
CN113473993B (zh) 2024-06-04
JP2022524930A (ja) 2022-05-11
US12350283B2 (en) 2025-07-08
US20220160745A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
EP2187882B1 (en) Treatment of progressive neurodegenerative disease with ibudilast
US20110105510A1 (en) Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
CN113244396A (zh) 靶向nad+以治疗化学和放射疗法引发的认知损害、神经病变和不活动
KR20120098578A (ko) 피로의 치료 또는 예방 방법
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
US11730751B2 (en) Treating and preventing motor neuron diseases using nicotinamide riboside
CN113473993B (zh) 治疗运动神经元疾病的方法和组合物
US20230381121A1 (en) N-palmitoylethanolamide and melatonin for use in the treatment of autism spectrum disorder and other neurobehavioral disorders similarly accompanied by restlessness, irritability, sleep disorders, and potentially stereotypies
AU2021365138A9 (en) Administration of antipurinergic compositions for treating nervous system disorders
CA3231869A1 (en) Ibudilast in combination therapy for use in the treatment of glioblastoma
EP2244702B1 (en) Treatment of neural diseases or conditions
KR101786818B1 (ko) 신경장애성 동통의 치료제 또는 예방제
US20230104124A1 (en) N-palmitoylethanolamide and docosahexaenoic acid for use in the treatment of autism spectrum disorder and other depressive syndromes
TWI544928B (zh) 麥角固醇於製造藥劑之用途
KR20260048558A (ko) 아필리모드 조성물 및 사용 방법
JPS615016A (ja) 活性酸素除去剤
WO2026102345A1 (en) Methods of administering the voltage-gated potassium channel opener azetukalner
CN113473977A (zh) 用于治疗线粒体疾病用途的大麻二酚和/或其衍生物
Wang et al. The treatment effects of HET0016 on demyelinating Mice induced by cuprizone
HK1241697A1 (en) Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis
HK1241697B (en) Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241029

R150 Certificate of patent or registration of utility model

Ref document number: 7580380

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150